REEV, a medtech company based in Toulouse, France, has raised $9.2 million to further its development of wearable robotics aimed at aiding individuals with mobility impairments. The startup focuses on creating lightweight, intelligent orthotic solutions to assist those with neurological conditions. With this funding, REEV plans to refine its technology, conduct clinical trials, and prepare for U.S. regulatory approval. The company’s mission is to improve mobility solutions by making assistive devices more adaptable and accessible. This investment is expected to accelerate the company’s expansion into new markets and enhance its product offerings.
REEV’s latest funding round builds on previous financial backing from investors who have supported its mission to develop next-generation mobility solutions. Compared to prior fundraising efforts, this round has attracted a broader range of investors, including healthcare professionals and athletes, highlighting growing interest in wearable robotics for medical applications. The company has consistently prioritized reducing the size and weight of assistive devices while improving their effectiveness. Earlier technological advancements in this field faced challenges related to affordability and ease of use, which REEV aims to address with its latest innovations.
How will the funds be used?
The funding will be used to finalize the design of DREEVEN, an electro-hydraulic motorized orthosis tailored for individuals with mobility impairments. A clinical study will be conducted at the Neuromotor Recovery Lab at Boston University’s Sargent College of Health & Rehabilitation Sciences, led by Dr. Lou Awad. The company will also allocate resources to meet the regulatory requirements necessary for U.S. Food and Drug Administration (FDA) approval.
“With the support of our world-class partners, we are thrilled to enter the next phase of clinical and industrial development,”
said Amaury Ciurana, Co-Founder and CEO of REEV. He emphasized that their technology aims to improve mobility solutions for users and reshape the orthotics industry.
What are REEV’s key products?
REEV has developed two primary technologies: REEV SENSE and DREEVEN. REEV SENSE is a motion sensor system that analyzes a patient’s walking patterns, while DREEVEN is a wearable robotic device designed to provide personalized knee support. The company’s focus is on reducing the weight and cost of these devices while increasing their adaptability to individual users. By addressing the limitations of traditional exoskeletons, REEV seeks to improve mobility assistance solutions.
The investment round was led by Newfund Heka, Polytechnique Ventures, and Irdi Capital, with additional backing from Techstars and individual investors, including French soccer player Raphael Varane and knee surgeon Herve Silbert. Newfund, a venture capital firm focused on early-stage innovations, has reaffirmed its commitment to supporting REEV’s efforts toward U.S. market entry.
“We are proud to continue supporting REEV as they work toward FDA clearance to bring their technology to market in the U.S.,”
said Anne-Sophie Saint-Martin, Partner at Newfund.
Since its founding in 2021 by Amaury Ciurana and Dr. Robin Temporelli, REEV has aimed to develop advanced assistive technology to help individuals with mobility impairments regain independence. The company plans to release the first series of DREEVEN in 2026, following regulatory approvals and clinical validation. Early user testing has already begun, allowing REEV to refine its product based on real-world feedback. The company’s approach focuses on making wearable robotics more intuitive and efficient for daily use.
Developing effective wearable robotics requires balancing lightweight design with sufficient support for users. Traditional exoskeletons have often been bulky and expensive, limiting their accessibility. REEV’s focus on electro-hydraulic technology aims to address these concerns while ensuring better adaptability for users. One challenge remains the integration of these devices into everyday life, which will require extensive testing and user feedback. The upcoming clinical studies will play a crucial role in determining the effectiveness of REEV’s solutions. As assistive technology continues to evolve, companies like REEV seek to bridge the gap between functionality and user convenience.
